The Dark Side of Curing Cancer

Panelists at AACR discuss the health risks that cancer survivors must face.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NCIAs researchers at this year's American Association for Cancer Research (AACR) meeting presented on promising new treatments for diverse cancer types, one group of experts pointed to the knock-on effects of these therapeutics: long-term health effects of the treatments themselves. “As [a] cure became possible, we started to recognize treatment-related late effects,” said Smita Bhatia, who studies the long-term health and well-being of cancer survivors at City of Hope in Duarte, California.

As of 2012, there were 13.7 million cancer survivors in the U.S.. By 2022, that number is expected to reach 18 million. These patients will face higher risks of secondary cancers, cardiovascular disease, psychosocial issues, and other health problems. “It’s well established that treatment can induce a second malignancy or other late effects,” said Lois Travis from the University of Rochester Medical Center in New York, who noted that the increasing number of cancer survivors is also a significant driver of health-care costs.

Pediatric cancer survivors are of particular interest, because they face “a long duration of future life years in which to manifest some of these complications” said Leslie Robison of St. Jude Children’s Research Hospital. Pediatric cancer survivors are at an up to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Skip the Wait for Protein Stability Data with Aunty

Skip the Wait for Protein Stability Data with Aunty

Unchained Labs

Products

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform

nuclera logo

Nuclera eProtein Discovery System installed at leading Universities in Taiwan

Brandtech Logo

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control